ReviewPharmacoEconomics1995
Criteria for drug usage review of thrombolytics in acute myocardial infarction.
Review in PharmacoEconomics, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction.PharmacoEconomics · 1996Review
- Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.PharmacoEconomics · 1995Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombolytic drugs are now the mainstay of the management of acute myocardial infarction (AMI). Although their use is associated with reduced mortality, significant adverse effects can occur, especially if they are used inappropriately. Drug usage review of this group of drugs provides a measure of the appropriateness of their use. The development of criteria against which the use of these drugs can be compared allows the collection of qualitative and quantitative data on their use. Those criteria identified during this process include: evidence for, and accuracy of, diagnosis of AMI; when, where and how to administer the drug; what drug to use, and at what dose. Identification of potential adverse effects, measures of treatment success and the role of adjunctive therapy may also be included as part of a drug usage evaluation process.
Indexed as
Identifiers
10155291What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.